Antitissue transglutaminase antibodies' normalization after starting a gluten-free diet in a large population of celiac children-a real-life experience

Dig Liver Dis. 2022 Mar;54(3):336-342. doi: 10.1016/j.dld.2021.06.026. Epub 2021 Jul 14.

Abstract

Introduction: Few data are available regarding the trend of IgA anti-transglutaminase antibodies (TGA-IgA) in children with celiac disease (CD) on a gluten-free diet (GFD). Our aim is to examine the normalization time of CD serology in a large pediatric population, and its predictors.

Material and methods: We retrospectively evaluated the normalization time of TGA-IgA and its predictive factors (age, sex, ethnicity, symptoms, associated diabetes/thyroiditis, Marsh stage, TGA-IgA and endomysial antibody levels at diagnosis, diet adherence), in 1024 children diagnosed from 2000 to 2019 in three pediatric Italian centers, on a GFD.

Results: TGA-IgA remission was reached in 67,3%, 80,7%, 89,8% and 94,9% after 12, 18, 24 and 36 months from starting a GFD, respectively (median time = 9 months). TGA-IgA >10´upper limit of normal at diagnosis (HR = 0.56), age 7-12 years old (HR = 0.83), poor compliance to diet (HR = 0.69), female sex (HR = 0.82), non-Caucasian ethnicity (HR = 0.75), and comorbidities (HR = 0.72) were independent factors significantly associated with longer time to normalization.

Conclusions: Our population is the largest in the literature, with the majority of patients normalizing CD serology within 24 months from starting a GFD. We suggest a special attention to patients with comorbidities, language barriers or age 7-12 years for a proper management and follow-up.

Keywords: Celiac disease; Independent predictors; Trend of serology normalization.

Publication types

  • Evaluation Study

MeSH terms

  • Autoantibodies / blood*
  • Celiac Disease / blood*
  • Celiac Disease / diet therapy
  • Child
  • Diet, Gluten-Free*
  • Female
  • Humans
  • Immunoglobulin A / blood*
  • Immunoglobulin A / immunology
  • Male
  • Patient Compliance / statistics & numerical data
  • Retrospective Studies
  • Transglutaminases / immunology*
  • Treatment Outcome

Substances

  • Autoantibodies
  • Immunoglobulin A
  • Transglutaminases